Skip to content
Safety ProfileEvidence-Based

Anamorelin Side Effects

Honest, evidence-based safety analysis for Anamorelin. Frequency data, severity classification, data limitations, and what we genuinely don't know.

Quick Answer

Common side effects of anamorelin include hyperglycemia, peripheral edema, nausea, and QTc prolongation. Liver enzyme elevation is also a possible but rare side effect. Careful monitoring is recommended, especially in patients with pre-existing conditions or risk factors.

→ Anamorelin Dosage→ Anamorelin Benefits→ Full Anamorelin Profile
Table of Contents

Data Context: What We Actually Know

Important: data limitations

The side effect profile of anamorelin is primarily based on clinical trial data from the ROMANA studies. Post-marketing surveillance may reveal additional side effects. The frequency and severity of side effects may vary among individuals.

Side Effects by Severity

MildModerateSevere / Serious
HyperglycemiaModerate

Frequency: Common (5-10%)

Monitor blood glucose levels regularly, especially in diabetic patients. May require adjustments to diabetes medication.

Peripheral edemaMild

Frequency: Common (3-5%)

Monitor for fluid retention. May require diuretics in some cases. Elevating legs and restricting sodium intake may help.

QTc prolongationSevere / Serious

Frequency: Rare

ECG monitoring is recommended, especially in patients with cardiac risk factors. Avoid concomitant use with other QTc-prolonging medications.

NauseaMild

Frequency: Common

May be transient. Consider antiemetics if nausea is persistent or severe.

Liver enzyme elevationMild

Frequency: Rare

Monitor liver function tests periodically.

Contraindications

  • ✕Hypersensitivity to anamorelin or any of its components
  • ✕Severe hepatic impairment
  • ✕Uncorrected electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia)
  • ✕Significant cardiac disease (e.g., heart failure, recent myocardial infarction)

Drug Interactions

No formal pharmacokinetic drug interaction studies have been conducted for most research peptides. The interactions below are theoretical, mechanism-based, or derived from limited case reports.
  • ⚠QTc-prolonging medications (e.g., antiarrhythmics, antipsychotics, certain antibiotics): increased risk of QTc prolongation
  • ⚠Insulin and oral hypoglycemic agents: may require dose adjustments due to anamorelin-induced hyperglycemia
  • ⚠CYP3A4 inhibitors/inducers: may affect anamorelin metabolism and plasma concentrations

Frequently Asked Questions

What are the most common side effects of anamorelin?
The most common side effects include hyperglycemia, peripheral edema, nausea, and QTc prolongation. Monitor blood glucose, fluid retention, and heart function.
Can anamorelin cause heart problems?
Anamorelin can prolong the QTc interval, which may increase the risk of arrhythmias. ECG monitoring is recommended, especially in patients with cardiac risk factors.
Does anamorelin interact with other medications?
Yes, anamorelin can interact with QTc-prolonging medications, insulin, oral hypoglycemic agents, and CYP3A4 inhibitors/inducers. Consult with a healthcare provider regarding potential drug interactions.
What should I do if I experience side effects while taking anamorelin?
Contact your healthcare provider if you experience any concerning side effects. They may adjust your dosage or recommend other interventions.
How often should I monitor my blood sugar while taking anamorelin?
Monitor blood glucose levels regularly, especially if you have diabetes or are at risk of developing hyperglycemia. Follow your healthcare provider's recommendations.

References

  1. 1
    Anamorelin for patients with cancer cachexia: ROMANA 1 and ROMANA 2 phase 3 trials(2015)PubMed ↗
  2. 2
    Anamorelin for the treatment of cancer anorexia-cachexia: ROMANA 3 extension trial(2017)PubMed ↗
  3. 3
    Safety and tolerability of anamorelin in healthy subjects: a phase 1, randomized, double-blind, placebo-controlled study.(2013)PubMed ↗

Last updated: 2026-02-19